Analysis of the Complete Open Reading Frame of Hepatitis C Virus in Genotype 2a Infection Reveals Critical Sites Influencing the Response to Peginterferon and Ribavirin Therapy

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2011 Apr 13

PMID 21484117

Citations 5

Authors

Makoto Kadokura

Shinya Maekawa

Ryota Sueki

Mika Miura

Kazuki Komase

Hiroko Shindo

Fumitake Amemiya

Tomoyoshi Uetake

Taisuke Inoue

Minoru Sakamoto

Mina Nakagawa

Naoya Sakamoto

Mamoru Watanabe

Nobuyuki Enomoto

Affiliations

Soon will be listed here.

Abstract

Purpose: A proportion of patients infected with genotype 2a hepatitis C virus (HCV) cannot achieve a sustained virological response (SVR) to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV) but the reason remains unclear. The present study aimed to clarify the possible correlation between viral sequence variations and final outcome.

Methods: The pretreatment complete open reading frame (ORF) sequences of genotype 2a HCV were determined by direct sequencing for two independent groups of patients (43 patients as test; group 1 and 35 as validation; group 2), and the correlation with the final outcome was explored.

Results: Patients with SVR (n = 58) and with non-SVR (n = 20) differed significantly in pretreatment HCV RNA level (p = 0.002), fibrosis score (p = 0.047), and cumulative RBV dosage (p = 0.003). By comparison of all amino acid positions in the complete HCV ORFs, threonine at amino acid (aa) 110 in the core region was remarkably frequent in SVR (p = 0.01 for group 1, p = 0.004 for group 2, and p = 5E-05 for combined). A sliding window analysis revealed that the total number of amino acid variations within the NS5A aa 2258-2306 region were significantly high in SVR compared to non-SVR patients (p = 0.01 for group 1, p = 0.006 for group 2, and p = 0.0006 for combined). Multivariate analyses revealed that core aa 110 (p = 0.02), NS5A aa 2258-2306 (p = 0.03), and cumulative RBV dosage (p = 0.02) were identified as independent variables associated with the final outcome.

Conclusions: The outcome of PEG-IFN/RBV therapy is significantly influenced by variation in the core and NS5A regions in genotype 2a HCV infection.

Citing Articles

Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.

Nakamoto S, Imazeki F, Arai M, Yasui S, Nakamura M, Haga Y Int J Mol Sci. 2015; 16(9):21177-90.

PMID: 26370958 PMC: 4613248. DOI: 10.3390/ijms160921177.

Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

El-Shamy A, Hotta H World J Gastroenterol. 2014; 20(24):7555-69.

PMID: 24976696 PMC: 4069287. DOI: 10.3748/wjg.v20.i24.7555.

Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Perales C, Beach N, Gallego I, Soria M, Quer J, Esteban J J Virol. 2013; 87(13):7593-607.

PMID: 23637397 PMC: 3700284. DOI: 10.1128/JVI.02824-12.

Sequence heterogeneity in NS5A of hepatitis C virus genotypes 2a and 2b and clinical outcome of pegylated-interferon/ribavirin therapy.

El-Shamy A, Shoji I, Kim S, Ide Y, Imoto S, Deng L PLoS One. 2012; 7(2):e30513.

PMID: 22319571 PMC: 3271109. DOI: 10.1371/journal.pone.0030513.

Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy.

Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H PLoS One. 2011; 6(9):e24514.

PMID: 21935415 PMC: 3174186. DOI: 10.1371/journal.pone.0024514.

References

Kobayashi M, Watanabe K, Ishigami M, Murase K, Ito H, Ukai K . Amino acid substitutions in the nonstructural region 5A of hepatitis C virus genotypes 2a and 2b and its relation to viral load and response to interferon. Am J Gastroenterol. 2002; 97(4):988-98. DOI: 10.1111/j.1572-0241.2002.05619.x. View

Mangia A, Santoro R, Minerva N, Ricci G, Carretta V, Persico M . Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005; 352(25):2609-17. DOI: 10.1056/NEJMoa042608. View

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H . Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy. Intervirology. 2009; 52(6):301-9. DOI: 10.1159/000235909. View

Ge D, Fellay J, Thompson A, Simon J, Shianna K, Urban T . Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401. DOI: 10.1038/nature08309. View

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y . Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy. J Med Virol. 2009; 81(3):459-66. DOI: 10.1002/jmv.21407. View

Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M . Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol. 2005; 20(9):1401-9. DOI: 10.1111/j.1440-1746.2005.04024.x. View

Murakami T, Enomoto N, Kurosaki M, Izumi N, Marumo F, Sato C . Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology. 1999; 30(4):1045-53. DOI: 10.1002/hep.510300405. View

Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View

10.

Watanabe H, Nagayama K, Enomoto N, Itakura J, Tanabe Y, Sato C . Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. Hepatol Res. 2003; 26(4):268-274. DOI: 10.1016/s1386-6346(03)00164-5. View

11.

Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, Saitoh S . Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. Hepatology. 2000; 32(5):1138-44. DOI: 10.1053/jhep.2000.19364. View

12.

Rauch A, Kutalik Z, Descombes P, Cai T, di Iulio J, Mueller T . Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4):1338-45, 1345.e1-7. DOI: 10.1053/j.gastro.2009.12.056. View

13.

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T . Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 2005; 48(6):372-80. DOI: 10.1159/000086064. View

14.

Toyoda H, Kumada T, Tada T, Arakawa T, Hayashi K, Honda T . Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. J Gastroenterol Hepatol. 2010; 25(6):1072-8. DOI: 10.1111/j.1440-1746.2010.06240.x. View

15.

Ghany M, Strader D, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-74. PMC: 7477893. DOI: 10.1002/hep.22759. View

16.

Donlin M, Cannon N, Yao E, Li J, Wahed A, Taylor M . Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007; 81(15):8211-24. PMC: 1951276. DOI: 10.1128/JVI.00487-07. View

17.

Dalgard O, Bjoro K, Hellum K, Myrvang B, Ritland S, Skaug K . Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004; 40(6):1260-5. DOI: 10.1002/hep.20467. View

18.

Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C . Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996; 334(2):77-81. DOI: 10.1056/NEJM199601113340203. View

19.

Di Bisceglie A, MARTIN P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J . Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989; 321(22):1506-10. DOI: 10.1056/NEJM198911303212204. View

20.

Simmonds P . Clinical relevance of hepatitis C virus genotypes. Gut. 1997; 40(3):291-3. PMC: 1027074. DOI: 10.1136/gut.40.3.291. View